Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

September 5, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

April 30, 2013

Conditions
Kidney Cancer
Interventions
DRUG

sunitinib malate

Trial Locations (22)

13273

Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille

13385

CHU de la Timone, Marseille

14076

Centre Regional Francois Baclesse, Caen

25030

Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besançon

29609

C.H.U. de Brest, Brest

31052

Institut Claudius Regaud, Toulouse

33075

Hopital Saint Andre, Bordeaux

34298

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier

37044

Centre Hospitalier Universitaire Bretonneau de Tours, Tours

38043

CHU de Grenoble - Hopital de la Tronche, Grenoble

44805

CRLCC Nantes - Atlantique, Nantes-Saint Herblain

49036

Centre Paul Papin, Angers

51056

Institut Jean Godinot, Reims

57038

Hopital Notre-Dame de Bon Secours, Metz

59020

Centre Oscar Lambret, Lille

69373

Centre Leon Berard, Lyon

75015

Hopital Europeen Georges Pompidou, Paris

Hopital Saint Michel, Paris

85025

Centre Hospitalier Departemental, La Roche-sur-Yon

92151

Hopital Foch, Suresnes

06189

Centre Antoine Lacassagne, Nice

F-94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

UNICANCER

OTHER

NCT00541008 - Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer | Biotech Hunter | Biotech Hunter